149 related articles for article (PubMed ID: 25264279)
1. Characterization of a novel butyrylcholinesterase point mutation (p.Ala34Val), "silent" with mivacurium.
Delacour H; Lushchekina S; Mabboux I; Ceppa F; Masson P; Schopfer LM; Lockridge O
Biochem Pharmacol; 2014 Dec; 92(3):476-83. PubMed ID: 25264279
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.
Delacour H; Lushchekina S; Mabboux I; Bousquet A; Ceppa F; Schopfer LM; Lockridge O; Masson P
PLoS One; 2014; 9(7):e101552. PubMed ID: 25054547
[TBL] [Abstract][Full Text] [Related]
3. Two novel mutations in the BCHE gene in patients with prolonged duration of action of mivacurium or succinylcholine during anaesthesia.
Gätke MR; Bundgaard JR; Viby-Mogensen J
Pharmacogenet Genomics; 2007 Nov; 17(11):995-9. PubMed ID: 18075469
[TBL] [Abstract][Full Text] [Related]
4. Patients with prolonged effect of succinylcholine or mivacurium had novel mutations in the butyrylcholinesterase gene.
Wichmann S; Færk G; Bundgaard JR; Gätke MR
Pharmacogenet Genomics; 2016 Jul; 26(7):351-6. PubMed ID: 27031121
[TBL] [Abstract][Full Text] [Related]
5. Response to mivacurium in a patient compound heterozygous for a novel and a known silent mutation in the butyrylcholinesterase gene: genotyping by sequencing.
Gätke MR; Ostergaard D; Bundgaard JR; Varin F; Viby-Mogensen J
Anesthesiology; 2001 Sep; 95(3):600-6. PubMed ID: 11575530
[TBL] [Abstract][Full Text] [Related]
6. Understanding the non-catalytic behavior of human butyrylcholinesterase silent variants: Comparison of wild-type enzyme, catalytically active Ala328Cys mutant, and silent Ala328Asp variant.
Lushchekina S; Nemukhin A; Varfolomeev S; Masson P
Chem Biol Interact; 2016 Nov; 259(Pt B):223-232. PubMed ID: 27062896
[TBL] [Abstract][Full Text] [Related]
7. Screening patients with prolonged neuromuscular blockade after succinylcholine and mivacurium.
Cerf C; Mesguish M; Gabriel I; Amselem S; Duvaldestin P
Anesth Analg; 2002 Feb; 94(2):461-6, table of contents. PubMed ID: 11812719
[TBL] [Abstract][Full Text] [Related]
8. Timing of blood sampling for butyrylcholinesterase phenotyping in patients with prolonged neuromuscular block after mivacurium or suxamethonium.
Mintjens N; Brummans R; Soetens F; Claes KBM; Vanlinthout LE
Acta Anaesthesiol Scand; 2021 Feb; 65(2):182-187. PubMed ID: 33010031
[TBL] [Abstract][Full Text] [Related]
9. [Danish Cholinesterase Research Unit diagnoses patients with prolonged paralysis after succinylcholine and mivacurium].
Eskildsen KZ; Gätke MR
Ugeskr Laeger; 2015 Apr; 177(18):866-8. PubMed ID: 26539575
[TBL] [Abstract][Full Text] [Related]
10. [Danish Cholinesterase Research Unit diagnoses patients with prolonged paralysis after succinylcholine and mivacurium].
Eskildsen KZ; Gätke MR
Ugeskr Laeger; 2014 Mar; 176(12A):. PubMed ID: 25350885
[TBL] [Abstract][Full Text] [Related]
11. Human butyrylcholinesterase polymorphism: Molecular modeling.
Lushchekina S; Delacour H; Lockridge O; Masson P
Int J Risk Saf Med; 2015; 27 Suppl 1():S80-1. PubMed ID: 26639724
[TBL] [Abstract][Full Text] [Related]
12. Response to mivacurium in patients carrying the k variant in the butyrylcholinesterase gene.
Gätke MR; Viby-Mogensen J; Ostergaard D; Bundgaard JR
Anesthesiology; 2005 Mar; 102(3):503-8. PubMed ID: 15731585
[TBL] [Abstract][Full Text] [Related]
13. Characterization of four BCHE mutations associated with prolonged effect of suxamethonium.
Brazzolotto X; Courcelle S; Sauvanet C; Guillon V; Igert A; Kononchik J; Nachon F; Ceppa F; Delacour H
Pharmacogenomics J; 2021 Apr; 21(2):165-173. PubMed ID: 33024248
[TBL] [Abstract][Full Text] [Related]
14. [Prolonged curarization with mivacurium and suxamethonium: will molecular biology allow a diagnostic and therapeutic approach?].
Duvaldestin P
Ann Fr Anesth Reanim; 1995; 14(6):465-6. PubMed ID: 8745968
[No Abstract] [Full Text] [Related]
15. Markedly prolonged paralysis after mivacurium in a patient apparently heterozygous for the atypical and usual pseudocholinesterase alleles by conventional biochemical testing.
Rosenberg MK; Lebenbom-Mansour M
Anesth Analg; 1997 Feb; 84(2):457-60. PubMed ID: 9024049
[No Abstract] [Full Text] [Related]
16. Interaction between the peripheral site residues of human butyrylcholinesterase, D70 and Y332, in binding and hydrolysis of substrates.
Masson P; Xie W; Froment MT; Levitsky V; Fortier PL; Albaret C; Lockridge O
Biochim Biophys Acta; 1999 Aug; 1433(1-2):281-93. PubMed ID: 10446378
[TBL] [Abstract][Full Text] [Related]
17. [Prolonged neuromuscular block after mivacurium injection].
Viggiano M; Soler C; Dumont JC; Pellissier D; François G
Ann Fr Anesth Reanim; 1995; 14(6):502-4. PubMed ID: 8745974
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block.
Beaufort TM; Nigrovic V; Proost JH; Houwertjes MC; Wierda JM
Anesthesiology; 1998 Sep; 89(3):707-14. PubMed ID: 9743409
[TBL] [Abstract][Full Text] [Related]
19. Butyrylcholinesterase deficiency.
Delacour H; Dedome E; Courcelle S; Hary B; Ceppa F
Ann Biol Clin (Paris); 2016 Jun; 74(3):279-85. PubMed ID: 27237801
[TBL] [Abstract][Full Text] [Related]
20. [Value of the monitoring of curarisation during prolonged mivacurium induced neuromuscular block].
Avargues P; Cros AM; Dardel E; Darriet M; Biteau N
Ann Fr Anesth Reanim; 1995; 14(6):511-3. PubMed ID: 8745977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
